News | September 12, 2012

New source of nuclear imaging tracers will offer alternative source for radiopharmaceuticals

September 12, 2012  – Positron Corp. announced that Jubilant DraxImage Inc., a Jubilant Life Sciences company, and Positron, have executed a Letter of Intent pertaining to:

  • Positron's supply of Active Pharmaceutical Ingredient (API) grade strontium (Sr)-82 for the JDI Sr-82/rubidium (Rb)-82 generator;
  • JDI's and Positron's co-promotion of JDI Sr-82/Rb-82 generators to end-users (upon FDA clearance); and
  • Positron's lifecycle management for expired JDI Sr-82/Rb-82 generators.

 

The strategic alliance between JDI and Positron will facilitate the stabilization, security and growth of the industry by increasing the supply of radioisotopes and radiopharmaceuticals. The parties expect that it will also provide considerable benefits to both parties: Positron secures a generator supply for future sales of cardiac positron emission tomography (PET) scanners and a customer for Sr-82; JDI secures a reliable supply of Sr-82, a vendor for expired generators management and a strategic partner with a growing customer base of cardiac PET scanners installed and serviced.

Martyn Coombs, president of JDI, stated, "Through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), Positron positioned itself as the only private entity in the United States with the practical experience of servicing the Sr-82/Rb-82 generator lifecycle. Their ability to provide a more stable and secure supply of API Sr-82 and management of expired Sr-82/Rb-82 generators fits well with JDI's pre-launch strategy."

Patrick Rooney, chief executive officer of Positron, stated, "JDI has developed a robust Sr-82/Rb-82 generator and elution system. As the Sr-82/Rb-82 generator on the market has enjoyed tremendous growth and the merits of the technology have been validated many times over, we strongly believe that the arrival of an alternative, upon the U.S. Food and Drug Administration (FDA) clearance of JDI's generator, will be welcomed by the cardiac PET community."

JDI and Positron expect to complete a Definitive Agreement within three months.

For more information: www.draximage.com and www.positron.com


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Subscribe Now